Skip to main content
Signal8
Launch Terminal

Immunocore Holdings plc (IMCR)

Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Immunocore Holdings plc logo

Immunocore Holdings plc

NASDAQ:IMCRHealthcare
-2.49%$30.49
AH$30.49+0.00%vs close
Mkt Cap$1.57B
Float44.99M
O/S51.5M
Vol
$ Vol
RVOL
Inst Own101.1%
SI17.3%
Earnings
Dilution
Immunocore Holdings plc logoNASDAQ:IMCR$30.49-2.49%
Phase Distribution
15 lead-sponsored trials·5 active·3 completed
Phase 14
Phase 1/26
Phase 22
Phase 32
Not applicable1
(6 more as collaborator)
Status Overview
Not yet recruiting1
Recruiting4
Active, not recruiting1
Completed3
Stopped5
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Recruiting

    Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

    Tebentafusp, Tebentafusp with Pembrolizumab

    Advanced Melanoma

    Enrollment
    540
    Start
    Dec 2022
    Primary Completion
    Mar 2028est.
    Completion
    Jul 2028est.
    NCT05549297
  • Phase 3
    Recruiting

    IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

    Brenetafusp, Nivolumab

    Advanced Melanoma

    Enrollment
    680
    Start
    Jun 2024
    Primary Completion
    Oct 2027est.
    Completion
    Oct 2027est.
    NCT06112314
  • Phase 2
    Terminated

    IMCgp100-401 Rollover Study

    IMCgp100

    Malignant Melanoma

    Enrollment
    3
    Start
    Jan 2017
    Primary Completion
    Apr 2019
    Completion
    Apr 2019
    NCT02889861
  • Phase 2
    Completed

    Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

    IMCgp100, Dacarbazine

    Uveal Melanoma

    Enrollment
    378
    Start
    Oct 2017
    Primary Completion
    Oct 2020
    Completion
    Sep 2025
    NCT03070392
  • Phase 1/2
    Withdrawn

    Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

    Tebentafusp (IMCgp100)

    Malignant Melanoma

    Enrollment
    0
    Start
    Nov 2015
    Primary Completion
    Jun 2023
    Completion
    Sep 2023
    NCT02535078
  • Phase 1/2
    Completed

    A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

    IMCgp100

    Uveal Melanoma

    Enrollment
    146
    Start
    Feb 2016
    Primary Completion
    Mar 2020
    Completion
    Oct 2022
    NCT02570308
  • Phase 1/2
    Terminated

    Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

    IMCnyeso

    Select Advanced Solid Tumors

    Enrollment
    29
    Start
    Jun 2018
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT03515551
  • Phase 1/2
    Withdrawn

    Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

    IMC-C103C, Atezolizumab

    Select Advanced Solid Tumors

    Enrollment
    0
    Start
    May 2019est.
    Primary Completion
    Sep 2023est.
    Completion
    Sep 2023est.
    NCT03973333
  • Phase 1/2
    Active, not recruiting

    Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

    Brenetafusp, Brenetafusp and pembrolizumab

    Select Advanced Solid Tumors

    Enrollment
    410
    Start
    Feb 2020
    Primary Completion
    Oct 2026est.
    Completion
    Dec 2027est.
    NCT04262466
  • Phase 1/2
    Recruiting

    Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

    IMC-R117C, Chemotherapy drug

    Cancer, HLA-A*02:01-positive

    Enrollment
    600
    Start
    Jan 2024
    Primary Completion
    Nov 2026est.
    Completion
    Nov 2027est.
    NCT06840119
  • Phase 1
    Completed

    Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

    IMCgp100

    Malignant Melanoma

    Enrollment
    84
    Start
    Sep 2010
    Primary Completion
    Feb 2016
    Completion
    Feb 2017
    NCT01211262
  • Phase 1
    Withdrawn

    Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

    IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses

    Hepatitis B, Chronic

    Enrollment
    0
    Start
    Aug 2020
    Primary Completion
    Sep 2024est.
    Completion
    Dec 2024est.
    NCT05867056
  • Phase 1
    Recruiting

    Study of IMC-P115C in Advanced PRAME-Positive Cancers

    IMC-P115C

    PRAME Positive, Cancer +1

    Enrollment
    140
    Start
    Nov 2024
    Primary Completion
    Sep 2027est.
    Completion
    Aug 2029est.
    NCT07156136
  • Phase 1
    Not yet recruiting

    Study of IMC-S118AI in Type 1 Diabetes

    IMC-S118AI

    Type 1 Diabetes, Type 1 Diabetes (T1D) +1

    Enrollment
    154
    Start
    Apr 2026est.
    Primary Completion
    Nov 2030est.
    Completion
    Nov 2030est.
    NCT07493122
  • Expanded access
    Available

    A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

    Tebentafusp

    Uveal Melanoma

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT04960891
Search ClinicalTrials.gov for “Immunocore Holdings”